Tests pindolol benzoate to protect muscle during semaglutide weight loss
Tests a drug to limit muscle loss in adults with obesity taking semaglutide.
Plain-language title generated from the registry record
Registry title: A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Key facts
- Where
- Belgrade, Kragujevac, Niš, Novi Sad, and Pančevo, SerbiaSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07101939, who can take part
Where in Serbia
- Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje'Belgrade, SerbiaTaking people
- Clinical hospital center Bezanijska KosaBelgrade, SerbiaTaking people
- University Clinical Center of SerbiaBelgrade, SerbiaTaking people
- University Clinical Center KragujevacKragujevac, SerbiaTaking people
- Klinika Za Endocrinologiju, Dijabetes I Bolesti MetabolizmaNiš, SerbiaTaking people
- University Clinical Center of VojvodinaNovi Sad, SerbiaTaking people
- Opsta bolnica PancevoPančevo, SerbiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Actimed Therapeutics Ltd
- Trial code
- NCT07101939
- Record updated
- 17 February 2026
- Original description
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).Read full original descriptionShow less
A Two-part, Phase 2a Randomized, Part Parallel-group, Double-blind Placebo-controlled Cross-over Multi-center Study to Evaluate the Effect of Two Dose Levels of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass in Obese Patients During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).
Inclusion: Eligible for treatment with semaglutide; Have a BMI of ≥30.0 kg/m².
Exclusion: received a GLP-1RA (including semaglutide),; Type 2 diabetes mellitus who in the preceding 90 days have either:; had a HBA1C over 10.0%; Any cardiovascular event within previous 6 months, uncontrolled hypertension, known congestive heart failure, or angina during the past year; Known severe chronic obstructive pulmonary disease (COPD); Concomitant use of beta blockers and patients with contra indications to beta blockers; had a hypoglycaemic event,; lost >5 kg weight,.